POS-03.108: Impacts of intermittent androgen suppression on bone mineral density, fat metabolism and anemia in patients with locally advanced prostate cancer

Urology ◽  
2007 ◽  
Vol 70 (3) ◽  
pp. 306
Author(s):  
Y. Takezawa ◽  
M. Kobayashi ◽  
K. Ito ◽  
K. Suzuki ◽  
H. Yamanaka
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Advanced Prostate Cancer ◽  
Fat Metabolism ◽  
Locally Advanced ◽  
Mineral Density ◽  
Locally Advanced Prostate Cancer ◽  
Intermittent Androgen Suppression ◽  
Androgen Suppression

BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER

2004 ◽  
Vol 171 (6 Part 1) ◽  
pp. 2272-2276 ◽  
Author(s):  
PAUL R. SIEBER ◽  
DANNY L. KEILLER ◽  
RICHARD J. KAHNOSKI ◽  
JOSE GALLO ◽  
SCOTT MCFADDEN
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Mineral Density ◽  
Locally Advanced Prostate Cancer

scholarly journals Case: Testicular oligometastasis from prostate cancer — Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy

2017 ◽  
Vol 12 (1) ◽  
pp. E31-3 ◽  
Author(s):  
Chan-Kyung J. Cho ◽  
Samantha Sigurdson ◽  
Christopher M. Davidson ◽  
Michael Leveridge ◽  
Aamer Mahmud
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Advanced Prostate Cancer ◽  
External Beam Radiotherapy ◽  
Locally Advanced ◽  
Androgen Deprivation ◽  
High Dose ◽  
Locally Advanced Prostate Cancer ◽  
Intermittent Androgen Suppression ◽  
Androgen Suppression

Testicular oligometastasis secondary to prostate cancer is rare. We present a case where a patient with locally advanced prostate cancer was treated with high-dose external beam radiotherapy and two years of androgen-deprivation therapy, followed by intermittent androgen suppression. Three and a half years after initial diagnosis, he was found to have a painless testicular mass. Orchiectomy was performed and histopathology demonstrated metastatic prostatic adenocarcinoma. He remains in clinical remission on intermittent androgen suppression eight years following initial treatment, and over four years after presentation with testicular metastasis.

Sign in / Sign up

Export Citation Format

Share Document